| | | Human | infants | 400 international units (IU) daily. | Vitamin D prophylaxis in infancy. |
| | | Human | — | 2000 mg calcium (combined with 800 IU vitamin D daily). | Vitamin D Supplementation in Military Personnel: A Systematic Review of Randomized Controlled Trials. |
| | | Human | — | Not specified | Nutrition, bone, and aging: an integrative physiology approach. |
| | | Human | — | Not specified | Calcium and vitamin D supplementation: when and why. |
| | | Human | adults aged ≥65 years | Not specified | Dietary supplements and disease prevention - a global overview. |
| | | Human | patients on these agents | Not specified | Drugs that may harm bone: Mitigating the risk. |
| | | Human | athletes | Not specified | Considerations for the Consumption of Vitamin and Mineral Supplements in Athlete Populations. |
| | | Human | — | Not specified | B vitamins, homocysteine and bone health. |
| | | Human | — | Weekly high-dose vitamin D (exact dosage not specified). | Update: Vitamin D |
| | | Human | children living with HIV in sub-Saharan Africa | Weekly high-dose vitamin D (exact dosage not specified). | Update: Vitamin D |
| | | Human | — | Higher loading doses of vitamin D are needed for obese individuals to achieve normal serum levels (specific dosage not provided). | Vitamin D in obesity. |
| | | Human | population level and in patients with osteoporosis | 800-1000 IU/day for levels <50 nmol/L; upper safety limit of 10,000 IU/day. | Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). |
| | | Human | — | 400 IU/day for infants; supplementation beyond 1 year for high-risk groups. | Vitamin D in the healthy European paediatric population. |
| | | Human | — | 12,000 IU, 24,000 IU, or 48,000 IU of vitamin D3 orally each month. | Vitamin D supplementation in older people (VDOP): Study protocol for a randomised controlled intervention trial with monthly oral dosing with 12,000 IU, 24,000 IU or 48,000 IU of vitamin D₃. |
| | | Human | — | 400 IU/day (oral supplementation for infants up to 1 year). | Vitamin D in European children-statement from the European Academy of Paediatrics (EAP). |
| | | Human | sarcoidosis patients | Not specified | Current concepts regarding calcium metabolism and bone health in sarcoidosis. |
| | | Human | — | Not specified in the abstract. | Methods and procedures for: A randomized double-blind study investigating dose-dependent longitudinal effects of vitamin D supplementation on bone health. |
| | | Human | general adult population | Not specified | Vitamin D recommendations in clinical guidelines: A systematic review, quality evaluation and analysis of potential predictors. |
| | | Human | general adult population | Not specified | Vitamin D recommendations in clinical guidelines: A systematic review, quality evaluation and analysis of potential predictors. |
| | | Human | general adult population | Not specified | Vitamin D recommendations in clinical guidelines: A systematic review, quality evaluation and analysis of potential predictors. |
| | | Human | children 0-7 years | 80-320 IU daily for children 0-7 years; 720 IU daily for patients >8 years. | Osteoporosis and bone health in pediatric patients with epidermolysis bullosa: A scoping review. |
| | | Human | patients >8 years | 80-320 IU daily for children 0-7 years; 720 IU daily for patients >8 years. | Osteoporosis and bone health in pediatric patients with epidermolysis bullosa: A scoping review. |
| | | Human | healthy adults | Individualized dosing regimens (specific amounts not provided). | Clinical Practice Guidelines of the Latin American Federation of Endocrinology for the use of vitamin D in the maintenance of bone health: recommendations for the Latin American context. |
| | | Human | individuals with osteopenia | Individualized dosing regimens (specific amounts not provided). | Clinical Practice Guidelines of the Latin American Federation of Endocrinology for the use of vitamin D in the maintenance of bone health: recommendations for the Latin American context. |
| | | Human | osteoporosis patients | Individualized dosing regimens (specific amounts not provided). | Clinical Practice Guidelines of the Latin American Federation of Endocrinology for the use of vitamin D in the maintenance of bone health: recommendations for the Latin American context. |
| | | Human | institutionalized older adults | Individualized dosing regimens (specific amounts not provided). | Clinical Practice Guidelines of the Latin American Federation of Endocrinology for the use of vitamin D in the maintenance of bone health: recommendations for the Latin American context. |
| | | Human | individuals aged 18 and above | Individualized dosing regimens (specific amounts not provided). | Clinical Practice Guidelines of the Latin American Federation of Endocrinology for the use of vitamin D in the maintenance of bone health: recommendations for the Latin American context. |
| | | Human | other patient populations | Not mentioned | Vitamin D in Osteosarcopenic Obesity. |
| | | Human | — | 400 IU vitamin D₃ daily for infants at risk of low vitamin D. | Vitamin D and health in pregnancy, infants, children and adolescents in Australia and New Zealand: a position statement. |
| | | Human | children | 10-50 μg/day | Vitamin D in Toddlers, Preschool Children, and Adolescents. |
| | | Human | the general population | Not specified in the abstract. | Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. |
| | | Human | — | 20 μg (800 IU) vitamin D daily (calcium dosage not specified) | Vitamin D: do we get enough? A discussion between vitamin D experts in order to make a step towards the harmonisation of dietary reference intakes for vitamin D across Europe. |
| | | Human | — | Not specified | Outcomes of Vitamin D Supplementation in Adults Who are Deficient and Critically Ill: A Review of the Literature. |
| | | Human | adults with epilepsy | Higher doses (>1800 IU) were suggested for future trials, but specific dosages were not detailed in the abstract. | Vitamin D supplementation for bone health in adults with epilepsy: A systematic review. |
| | | Human | — | Not specified | Vitamin D Deficiency in Chronic Childhood Disorders: Importance of Screening and Prevention. |
| | | Human | — | Not specified | Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus. |
| | | Human | — | — | Vitamin D and health: the need for more randomized controlled trials. |
| | | Human | — | Not specified | 25-Hydroxyvitamin D as a Biomarker of Vitamin D Status and Its Modeling to Inform Strategies for Prevention of Vitamin D Deficiency within the Population. |
| | | Human | — | Not specified | Nutrition in Thalassemia: A Systematic Review of Deficiency, Relations to Morbidity, and Supplementation Recommendations. |
| | | Human | — | 600-800 IU of native vitamin D3 (recommended standard dose for the healthy population). | Vitamin D in critical care: where are we now and what is next? |
| | | Human | — | Not specified | Osteoporosis diagnosis and medical treatment. |
| | | Human | — | — | Vitamin D and thyroid disease: to D or not to D? |
| | | HumanMolecular | — | Not mentioned | Focus on vitamin D and the adrenal gland. |
| | | Human | pediatric age | Not specified | Vitamin D in childhood and adolescence: an expert position statement. |
| | | Human | — | Not specified | Calcium and Vitamin D Deficiency in Vietnamese: Recommendations for an Intervention Strategy. |
| | | HumanMolecular | — | Not specified | INFLUENCE OF VITAMIN D ON HUMAN HEALTH (REVIEW). |
| | | HumanMolecular | — | Not specified | INFLUENCE OF VITAMIN D ON HUMAN HEALTH (REVIEW). |
| | | Human | — | Not specified | Chronic Atrophic Autoimmune Gastritis: The Evolving Role of Vitamin D. |
| | | Human | — | Not specified | The role of carotenoids in bone health-A narrative review. |
| | | Human | postmenopausal women | — | A review of select vitamins and minerals used by postmenopausal women. |
| | | Human | — | Not specified | Vitamin D Supplementation in Patients with Juvenile Idiopathic Arthritis. |
| | | Human | people with multiple sclerosis (MS) | Not specified | Management of Osteoporosis, Fracture and Falls in People with Multiple Sclerosis: Systematic Review of Guidelines. |
| | | Human | — | Not specified | Correlation between vitamin D metabolic pathway-related gene polymorphisms and cardiovascular disease. |
| | | Human | — | Not specified | Relationship between vitamin D deficiency and gestational diabetes: a narrative review. |
| | | Human | — | Not specified | Unlocking the Potential of Vitamin D: A Comprehensive Exploration of Its Role in Neurological Health and Diseases. |
| | | Human | — | Not specified | Vitamin D and Respiratory Diseases : Based on 11th Dr. I. C. Verma Excellence in Research Award for Young Pediatricians Delivered as Oration on 15th Oct. 2023. |
| | | Human | — | Not mentioned | Vitamin D in schizophrenia: a clinical review. |
| | | Human | — | Not specified | Possible influence of vitamin D on male reproduction. |
| | | Human | — | Not mentioned | Vitamin D-Do Diet Recommendations for Health Remain Strong? |
| | | Human | — | Not specified | Targeting the Hallmarks of Aging with Vitamin D: Starting to Decode the Myth. |
| | | Human | women with a Z-score <-2.0 or Z-score ≤-1.0 and/or a 5-10% annual decrease in bone mineral density | Daily calcium supplementation (specific dosage not mentioned). | Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? |
| | | Human | premenopausal women with breast cancer | Daily calcium supplementation (specific dosage not mentioned). | Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? |
| | | Human | all subjects with osteopenia or osteoporosis | Not specified | Updated recommendations for the diagnosis and management of osteoporosis: a local perspective. |
| | | Human | patients with inflammatory bowel disease | Not specified | Pediatric inflammatory bowel disease and bone health. |
| | | Human | patients receiving ADT | Not specified | Adverse effects of androgen deprivation therapy in patients with prostate cancer: Focus on muscle and bone health. |
| | | Human | — | Not specified | Vitamin D and calcium: what do we need to know? |
| | | Human | postmenopausal women | Not specified | Vitamin D and calcium: what do we need to know? |
| | | Human | patients with epidermolysis bullosa (EB) | Not specified | Osteopenia and osteoporosis in epidermolysis bullosa. |
| | | Human | offspring | Not specified | Structured diet and exercise guidance in pregnancy to improve health in women and their offspring: study protocol for the Be Healthy in Pregnancy (BHIP) randomized controlled trial. |
| | | Human | adolescents with NTD Hb E/β-thalassemia | Not specified | Prevalence of low bone mass among adolescents with nontransfusion-dependent hemoglobin E/β-thalassemia and its relationship with anemia severity. |
| | | Human | maternal participants during pregnancy | Individualized high dairy protein diet (specific amounts not detailed). | Individualized high dairy protein + walking program supports bone health in pregnancy: a randomized controlled trial. |
| | | Human | — | Not specified | Perioperative Evaluation and Management of Children with Osteoporosis and Low Bone Mineral Density. |
| | | Human | postmenopausal women with osteoporosis | 1,200 mg calcium carbonate and 400 IU vitamin D3 daily. | Is a lower dose of vitamin D supplementation enough to increase 25(OH)D status in a sunny country? |
| | | Human | patients assessed for fracture risk | Not specified | Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). |
| | | Human | all patients with chronic liver disease | — | Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications. |
| | | Human | individuals with Rett syndrome | Not specified | Clinical Guidelines for Management of Bone Health in Rett Syndrome Based on Expert Consensus and Available Evidence. |
| | | Human | critically ill populations | Not specified | Micronutrient intake to protect against osteoporosis during and after critical illness. |
| | | Human | men treated with ADT for prostate cancer | Not specified | Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial. |
| | | Human | young adults entering IMT | 2000 mg calcium and 1000 IU vitamin D daily. | Association Between Single Gene Polymorphisms and Bone Biomarkers and Response to Calcium and Vitamin D Supplementation in Young Adults Undergoing Military Training. |
| | | Human | — | Not specified. | Vitamin D, Calcium Supplements, and Implications for Cardiovascular Health: JACC Focus Seminar. |
| | | Human | high-risk patients | 1,000 to 1,200 mg of calcium per day; 800 to 2,000 IU of vitamin D3 daily. | Current concept review: vitamin D and stress fractures. |
| | | Human | most adults | 1,000 to 1,200 mg of calcium per day; 800 to 2,000 IU of vitamin D3 daily. | Current concept review: vitamin D and stress fractures. |
| | | Human | offspring | Not specified | Prenatal calcium and vitamin D intake, and bone mass in later life. |
| | | Human | community-dwelling adults | Greater than 400 IU vitamin D3 and greater than 1000 mg calcium (for postmenopausal women); ≤400 IU vitamin D3 and ≤1000 mg calcium (not recommended). | Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. |
| | | Human | adults and children with celiac disease | Not specified | Management of bone health in patients with celiac disease: Practical guide for clinicians. |
| | | Human | regularly transfused beta-thalassemia major patients | Not specified | An Evaluation of Bone Health Parameters in Regularly Transfused Beta-Thalassemia Major Patients. |
| | | Human | women at high risk of osteoporosis | Not specified | Effects of a three-month therapeutic lifestyle modification program to improve bone health in postmenopausal Korean women in a rural community: a randomized controlled trial. |
| | | Human | — | Not specified. | Crucial Role of Vitamin D in the Musculoskeletal System. |
| | | Human | breast cancer survivors | Not specified | Vitamin D and breast cancer. |
| | | Human | children living with HIV in sub-Saharan Africa | Weekly high-dose vitamin D (specific amount not mentioned). | Vitamin D |
| | | Human | — | Not specified | Osteoporosis and dermatoporosis: a review on the role of vitamin D. |
| | | Human | — | Not specified | Vitamin D in dialysis: defining deficiency and rationale for supplementation. |
| | | Human | children and adults | Not specified (sunlight exposure varies; 400 IU vitamin D daily mentioned for infants). | Ultraviolet radiation: a hazard to children and adolescents. |
| | | Human | osteopenic individuals | 1200 mg calcium carbonate with 1000 IU vitamin D₃ daily | Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT. |
| | | Human | postmenopausal women receiving AIs | Not specified | Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors. |
| | | Human | older population | — | The cardiovascular safety aspects of calcium supplementations: where does the truth lie? A personal perspective. |
| | | Human | the offspring | Not specified | "You are my sunshine, my only sunshine": maternal vitamin D status and supplementation in pregnancy and their effect on neonatal and childhood outcomes. |
